NO20034629L - Oralt avleverbart farmasöytisk preparat innbefattende et tungt vannopplöselig legemiddel (cox-2 inhibitor), et opplösningsmiddel, en fettsyreog et organisk amin - Google Patents

Oralt avleverbart farmasöytisk preparat innbefattende et tungt vannopplöselig legemiddel (cox-2 inhibitor), et opplösningsmiddel, en fettsyreog et organisk amin

Info

Publication number
NO20034629L
NO20034629L NO20034629A NO20034629A NO20034629L NO 20034629 L NO20034629 L NO 20034629L NO 20034629 A NO20034629 A NO 20034629A NO 20034629 A NO20034629 A NO 20034629A NO 20034629 L NO20034629 L NO 20034629L
Authority
NO
Norway
Prior art keywords
cox
orally
inhibitor
solvent
pharmaceutical composition
Prior art date
Application number
NO20034629A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034629D0 (no
Inventor
Ping Gao
Aziz Karim
Fred Hassan
James C Forbes
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NO20034629D0 publication Critical patent/NO20034629D0/no
Publication of NO20034629L publication Critical patent/NO20034629L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20034629A 2001-04-17 2003-10-16 Oralt avleverbart farmasöytisk preparat innbefattende et tungt vannopplöselig legemiddel (cox-2 inhibitor), et opplösningsmiddel, en fettsyreog et organisk amin NO20034629L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28438101P 2001-04-17 2001-04-17
US32695201P 2001-10-04 2001-10-04
PCT/US2002/011689 WO2002083177A1 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Publications (2)

Publication Number Publication Date
NO20034629D0 NO20034629D0 (no) 2003-10-16
NO20034629L true NO20034629L (no) 2003-12-10

Family

ID=26962574

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034629A NO20034629L (no) 2001-04-17 2003-10-16 Oralt avleverbart farmasöytisk preparat innbefattende et tungt vannopplöselig legemiddel (cox-2 inhibitor), et opplösningsmiddel, en fettsyreog et organisk amin

Country Status (18)

Country Link
US (1) US20030105141A1 (enExample)
EP (1) EP1379279A1 (enExample)
JP (1) JP2004530669A (enExample)
KR (1) KR20040018355A (enExample)
CN (1) CN1516601A (enExample)
AR (1) AR033221A1 (enExample)
AU (1) AU2002305175B2 (enExample)
BR (1) BR0208994A (enExample)
CA (1) CA2444220A1 (enExample)
CZ (1) CZ20032792A3 (enExample)
EA (1) EA008103B1 (enExample)
IL (1) IL158201A0 (enExample)
MX (1) MXPA03009411A (enExample)
NO (1) NO20034629L (enExample)
NZ (1) NZ528741A (enExample)
PE (1) PE20021145A1 (enExample)
PL (1) PL364524A1 (enExample)
WO (1) WO2002083177A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
EP1653931A2 (en) * 2003-07-17 2006-05-10 Banner Pharmacaps, Inc. Controlled release preparations
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
CN101142198B (zh) * 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
CN101360485B (zh) * 2005-10-26 2013-04-17 班纳制药公司 作为胶囊填充物的基于亲水性载体的双重控释基质系统
JP5406529B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
WO2009040776A1 (en) * 2007-09-27 2009-04-02 Wockhardt Research Centre Self-emulsifying pharmaceutical compositions of rhein or diacerein
PL2367542T3 (pl) * 2008-12-03 2014-05-30 Astellas Deutschland Gmbh Doustne formy dawkowania bendamustyny
JP5951489B2 (ja) 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組成物
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
WO2011151087A1 (en) * 2010-06-02 2011-12-08 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
RU2630617C2 (ru) 2011-10-18 2017-09-11 Аскат Инк. Фармацевтическая композиция
PL3795141T3 (pl) * 2013-01-14 2025-11-12 Infirst Healthcare Limited Kompozycje w postaci roztworu stałego
BR112015015870B1 (pt) * 2013-02-04 2022-09-27 Infirst Healthcare Limited Uso de uma composição farmacêutica
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
EP3481923A4 (en) 2016-07-05 2019-12-18 Golden Renewable Energy, LLC SYSTEM AND METHOD FOR CONVERTING WASTE PLASTIC INTO FUEL
US12213510B2 (en) 2019-09-11 2025-02-04 Nicoventures Trading Limited Pouched products with enhanced flavor stability
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE233245T1 (de) * 1993-11-30 2003-03-15 Searle & Co Substituierte pyrazolyl-benzolsulfonamide und ihre verwendung als cyclooxygenaseii inhibitoren
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
WO1999009988A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US20020077328A1 (en) * 2000-07-13 2002-06-20 Fred Hassan Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain

Also Published As

Publication number Publication date
EP1379279A1 (en) 2004-01-14
AU2002305175B2 (en) 2007-07-12
WO2002083177A1 (en) 2002-10-24
NZ528741A (en) 2005-09-30
PE20021145A1 (es) 2003-01-16
CA2444220A1 (en) 2002-10-24
CN1516601A (zh) 2004-07-28
NO20034629D0 (no) 2003-10-16
US20030105141A1 (en) 2003-06-05
CZ20032792A3 (cs) 2004-04-14
KR20040018355A (ko) 2004-03-03
JP2004530669A (ja) 2004-10-07
EA200301019A1 (ru) 2004-06-24
IL158201A0 (en) 2004-05-12
MXPA03009411A (es) 2004-01-29
BR0208994A (pt) 2004-04-27
AR033221A1 (es) 2003-12-10
PL364524A1 (en) 2004-12-13
EA008103B1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
NO20034629D0 (no) Oralt avleverbart farmasöytisk preparat innbefattende et tungt vannopplöselig legemiddel (cox-2 inhibitor), et opplösningsmiddel, en fettsyreog et organisk amin
DK1480679T3 (da) Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat
TWI340034B (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
NO20033384L (no) Farmasoytisk formulering
DK1545467T3 (da) Faste farmaceutiske formuleringer omfattende telmisartan
NO20040564L (no) Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel
NO20040178L (no) Farmasoytisk formulering innebefattende en protonpumpeinhibitor og syrenoytraliserende midler
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
NO20031744D0 (no) Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike
ITTO20010008A0 (it) Formulazione farmaceutica
NO2014005I1 (no) olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav
ATE337793T1 (de) Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
DK1326864T3 (da) Sammenföjede aryl- eller heteroarylforbindelser som antiinflammatoriske og analgetiske midler
PT1501534E (pt) Formulacoes farmaceuticas
IS7298A (is) Platínuafleiða lyfjasamsetningar
DK1301485T3 (da) Nye heteroaryl-derivater og disses anvendelse som lægemiddel
DK1425019T3 (da) Farmaceutisk sammensætning omfattende et androgen
EP1496913A4 (en) NEUROPROTECTIVE PHARMACEUTICAL SPIROSTENOL COMPOSITIONS
BRPI0308445A2 (pt) complexos de rápida dissolução, diretamente compressíveis, sem sabor e formulações farmacêuticas dos mesmos
AU2003273335A1 (en) Method for testing drug susceptibility of hiv
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
EP1711490A4 (en) NEW P-GLYCOPROTEIN INHIBITOR, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
NO20054389D0 (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
EP1581196A4 (en) SÄURELABILE MEDICINAL COMPOSITIONS
AU2003265432A8 (en) Polyionic organic acid formulations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application